Sarepta Therapeutics Inc. (SRPT) Rating Reiterated by SunTrust Banks Inc.
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “hold” rating reissued by investment analysts at SunTrust Banks Inc. in a report released on Monday. They currently have a $52.00 price target on the stock. SunTrust Banks Inc.’s target price would indicate a potential upside of 4.25% from the company’s current price.
SRPT has been the subject of several other research reports. JMP Securities raised shares of Sarepta Therapeutics to an “outperform” rating and raised their target price for the stock from $10.00 to $60.00 in a report on Monday, September 19th. Royal Bank Of Canada raised shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 target price for the company in a report on Monday, September 19th. Cowen and Company reissued an “outperform” rating and set a $64.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, October 5th. Leerink Swann reissued an “underperform” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a report on Thursday, August 4th. Finally, Robert W. Baird reissued an “outperform” rating and set a $102.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and an average price target of $63.54.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 49.88 on Monday. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The stock has a 50 day moving average price of $46.30 and a 200 day moving average price of $27.13. The stock’s market cap is $2.39 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the firm earned ($0.87) EPS. On average, analysts forecast that Sarepta Therapeutics will post ($4.23) earnings per share for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,217,600.00. Following the sale, the chief executive officer now directly owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the completion of the sale, the vice president now directly owns 21,490 shares in the company, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its stake in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the period. Teacher Retirement System of Texas increased its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter worth about $211,000. Finally, First Allied Advisory Services Inc. increased its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. 65.06% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.